Fresenius Kabi Canada Ltd.
Fresenius Kabi Canada Ltd., a subsidiary of the global healthcare group Fresenius Kabi, is headquartered in Canada and operates extensively across the country. Founded in 1999, the company has established itself as a key player in the pharmaceutical and medical device industry, focusing on lifesaving medicines and technologies. Fresenius Kabi is renowned for its comprehensive portfolio, which includes intravenous (IV) drugs, infusion therapies, and clinical nutrition products. These offerings are distinguished by their commitment to quality and innovation, ensuring optimal patient care. With a strong market position, Fresenius Kabi Canada has achieved notable milestones, including advancements in biosimilars and a robust supply chain that supports healthcare providers nationwide.
DitchCarbon Score
How does Fresenius Kabi Canada Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Fresenius Kabi Canada Ltd.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Fresenius Kabi Canada Ltd., headquartered in Canada, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Fresenius SE & Co. KGaA, which may influence its climate commitments and emissions reporting. As part of its corporate family, emissions data and performance metrics are cascaded from Fresenius SE & Co. KGaA. However, no specific reduction targets or initiatives have been documented for Fresenius Kabi Canada Ltd. at this time. The absence of documented reduction targets suggests that the company may still be in the process of establishing its climate strategy or aligning with broader corporate sustainability goals. Fresenius Kabi Canada Ltd. is expected to adhere to the climate commitments set forth by its parent company, which may include industry-standard practices for emissions reduction and sustainability. As the company develops its own initiatives, it will likely focus on aligning with global standards and best practices in the pharmaceutical and healthcare sectors.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 521,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 1,013,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Fresenius Kabi Canada Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
